| __timestamp | AstraZeneca PLC | CymaBay Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5579000000 | 15823000 |
| Thursday, January 1, 2015 | 5997000000 | 17026000 |
| Friday, January 1, 2016 | 5890000000 | 15941000 |
| Sunday, January 1, 2017 | 5757000000 | 18938000 |
| Monday, January 1, 2018 | 5932000000 | 58124000 |
| Tuesday, January 1, 2019 | 5958000000 | 83837000 |
| Wednesday, January 1, 2020 | 5991000000 | 35882000 |
| Friday, January 1, 2021 | 9736000000 | 64542000 |
| Saturday, January 1, 2022 | 9762000000 | 67995000 |
| Sunday, January 1, 2023 | 10935000000 | 80118000 |
In pursuit of knowledge
In the competitive world of pharmaceuticals, research and development (R&D) spending is a key indicator of innovation and future growth. AstraZeneca PLC, a global biopharmaceutical giant, and CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, present a fascinating contrast in their R&D investments over the past decade.
From 2014 to 2023, AstraZeneca's R&D expenses have surged by nearly 96%, peaking at over $10 billion in 2023. This reflects their commitment to expanding their drug pipeline and maintaining a competitive edge. In contrast, CymaBay's R&D spending, while significantly smaller, has shown a remarkable increase of over 400% during the same period, reaching approximately $80 million in 2023. This growth underscores CymaBay's aggressive push to bring innovative therapies to market.
This showdown highlights the diverse strategies of established and emerging players in the pharmaceutical industry, each striving to make a mark in the world of medicine.
R&D Spending Showdown: AstraZeneca PLC vs Gilead Sciences, Inc.
Who Prioritizes Innovation? R&D Spending Compared for AstraZeneca PLC and Neurocrine Biosciences, Inc.
Research and Development Expenses Breakdown: AstraZeneca PLC vs Alpine Immune Sciences, Inc.
Who Prioritizes Innovation? R&D Spending Compared for AstraZeneca PLC and Arrowhead Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for AstraZeneca PLC and Wave Life Sciences Ltd.
Zoetis Inc. vs CymaBay Therapeutics, Inc.: Strategic Focus on R&D Spending
Analyzing R&D Budgets: Dr. Reddy's Laboratories Limited vs CymaBay Therapeutics, Inc.
Blueprint Medicines Corporation or CymaBay Therapeutics, Inc.: Who Invests More in Innovation?
R&D Insights: How CymaBay Therapeutics, Inc. and ACADIA Pharmaceuticals Inc. Allocate Funds
R&D Spending Showdown: CymaBay Therapeutics, Inc. vs Xenon Pharmaceuticals Inc.
Comparing Innovation Spending: CymaBay Therapeutics, Inc. and Bausch Health Companies Inc.
R&D Insights: How CymaBay Therapeutics, Inc. and Protagonist Therapeutics, Inc. Allocate Funds